Inhibikase Therapeutics Files Form 8-K on March 26 Inhibikase filed an SEC Form 8‑K on Mar 26, 2026; the SEC requires 8‑Ks within 4 business days — immediate EDGAR review is warranted.

Inhibikase Therapeutics Files Form 8-K on March 26: Inhibikase filed an SEC Form 8‑K on Mar 26, 2026; the SEC requires 8‑Ks within 4 business days — immediate EDGAR review is warranted. 👈 Read full analysis #Inhibikase #Therapeutics #SEC #Form8K #BusinessNews

Purcell & Lefkowitz LLP Investigates Inhibikase Therapeutics for Shareholder Rights Purcell & Lefkowitz LLP is conducting an investigation into Inhibikase Therapeutics, focusing on potential breaches of fiduciary duties by the company's directors.

Purcell & Lefkowitz LLP Investigates Inhibikase Therapeutics for Shareholder Rights #United_States #New_York #Purcell_&_Lefkowitz #Inhibikase #IKT